Dolutegravir Antiretroviral Strategy to Promote Improvement and Reduce Drug Exposure (ASPIRE) Study
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 24 Jan 2017
At a glance
- Drugs Dolutegravir (Primary) ; Lamivudine (Primary)
- Indications HIV-1 infections
- Focus Therapeutic Use
- Acronyms ASPIRE
- 07 Jun 2017 Biomarkers information updated
- 17 Jan 2017 Planned primary completion date changed from 1 Jun 2017 to 1 Mar 2017.
- 17 Jan 2017 Status changed from recruiting to active, no longer recruiting.